Memphasys Limited, formerly NuSep Holdings Limited, is a bio-separations company developing and commercializing separation techniques based on its membrane technology. The Company has two main areas of focus for separating biological substances from fluids, utilizing its separation membranes and equipment: SpermSep and Hydrogel polymer membrane technology development. Its segments include Separations and Corporate. The Separations segment develops and markets the PrIME technology in both the commercial and research markets, including the ProteomeSep and SpermSep devices. Its program, SpermSep, separates the sperm from a semen sample using electrophoresis and specialist membranes. The SpermSep technology is used in fertility treatments, including in vitro fertilization (IVF) for humans and in various artificial reproductive techniques (ART) for animals. It has developed a polymer membrane separation technology using polyacrylamide hydrogel membranes with electrophoresis.

Sales Analysis. During the year ended June of 2016, sales at Memphasys Ltd were A$63,960.00 (US$49.35 thousand). This is a sharp decrease of 66.5% versus 2015, when the company's sales were A$190,660.00 .